Story content courtesy of Okayama University, Japan
“In 2005 researchers at the Okayama University Medical School forced its expression using adenoviral vector (Ad-REIC) and discovered it caused selective death (apoptosis) of prostate cancer cells without damaging normal cells,” explains Professor Kumon. “Our approach is a combination of targeting and immunology for the treatment of cancer. Some people have referred to this as a ‘magic bullet’. We are working with international partners to develop an Ad-REIC/DKK3 vaccine to treat various intractable solid tumors.”
The important aspect of cancer treatment using Ad-REIC is that it is highly selective, and normal cells are not affected, where the action of Ad-REIC occurs almost 100% in prostate cancer, ~90% in malignant mesothelioma, and also high rates in other cases including kidney cancer.
Momotaro-Gene Inc—an Okayama University venture company— and Okayama University own the intellectual property for this treatment.